Caputy A J, McCullough D C, Manz H J, Patterson K, Hammock M K
J Neurosurg. 1987 Jan;66(1):80-7. doi: 10.3171/jns.1987.66.1.0080.
The clinical, therapeutic, and histological features of 54 patients with medulloblastoma were analyzed retrospectively by a multivariate approach with regard to prognosis. The overall 5-year survival rate was 60%, with 48% of patients free of recurrence at 5 years. Cell differentiation, when present, was associated with a significantly longer recurrence-free period. Seventy-two percent of patients with the histological finding of cell differentiation were recurrence-free at 5 years. A marginally significant increase in the 5-year survival rate was also seen in association with differentiation. Only 34% of the patients whose tumor exhibited necrosis were alive at 5 years. There was no statistically significant difference in 5-year survival for children under 3 years of age or for the group of children aged 5 years or under. However, a significantly larger fraction (72%) of the group aged 5 years or under had a recurrence-free period of 5 years or more. Other factors including sex, extent of surgical resection. Chang tumor stage, posterior fossa radiation dose, and adjuvant chemotherapy did not influence prognosis.
采用多变量方法对54例髓母细胞瘤患者的临床、治疗及组织学特征进行回顾性分析以评估预后。总体5年生存率为60%,48%的患者在5年时无复发。若存在细胞分化,则与显著更长的无复发生存期相关。组织学检查发现有细胞分化的患者中,72%在5年时无复发。分化也与5年生存率的略微显著提高相关。肿瘤出现坏死的患者中,只有34%在5年时仍存活。3岁以下儿童或5岁及以下儿童组的5年生存率无统计学显著差异。然而,5岁及以下儿童组中显著更大比例(72%)的患者无复发生存期达5年或更长。包括性别、手术切除范围、Chang肿瘤分期、后颅窝放疗剂量及辅助化疗在内的其他因素均不影响预后。